Conference Coverage

VIDEO: HFSA Roundtable, part 3: Acute heart failure decompensations pose uncertain consequences


 

EXPERT ANALYSIS FROM THE HFSA ANNUAL SCIENTIFIC MEETING

References

NATIONAL HARBOR, MD. – “There may be more to acute heart failure than meets the eye,” Hani N. Sabbah, Ph.D., said in a discussion during the annual meeting of the Heart Failure Society of America.

What remains unclear about acute decompensation episodes in patients with chronic heart failure is whether these events themselves exert a detrimental effect or if decompensation episodes merely flag patients in the worst clinical condition and are part of the natural history of worsening heart failure, said Dr. Sabbah, professor and director of cardiovascular research at Henry Ford Hospital in Detroit.

The importance of acute heart failure decompensations seems comparable to acute MIs, episodes in which incremental declines in heart-muscle function contribute to additional long-term worsening of heart failure, said Dr. Jay N. Cohn, another member of a discussion panel that also included Dr. Sidney Goldstein and Dr. Prakash Deedwania.

The risk from acute decompensations of heart failure highlights the importance of taking steps to cut the incidence of decompensations, said Dr. Cohn. Usual triggers of decompensation that could be targets for prevention are uncontrolled blood pressure and dietary indiscretions, Dr. Deedwania noted. Troponin leaks, a marker of myocardial-cell death, constitute another indicator of acute decompensation that may offer further insight into how to manage these episodes, he said.

Dr. Goldstein had no disclosures. Dr. Deedwania had no disclosures. Dr. Cohn receives royalties from Arbor Pharmaceuticals related to his work on hydralazine and isosorbide dinitrate. Dr. Sabbah is a consultant to Boston Scientific and an advisor to BioControl Medical and he has received research grants from both companies.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

Heart failure risk reduced with higher levels of physical activity
MDedge Internal Medicine
FDA approves combo therapy for pulmonary hypertension
MDedge Internal Medicine
ESC: Cancer itself may cause cardiotoxicity
MDedge Internal Medicine
ESC: What’s the hottest recent advance in cardiology? And the winner is …
MDedge Internal Medicine
TCT: CTO treatment after MI doesn’t benefit LV function
MDedge Internal Medicine
Depression, hypertension combo compounds cardiovascular risk
MDedge Internal Medicine
TCT: SAPIEN XT TAVR system gains valve-in-valve indication
MDedge Internal Medicine
HFSA: Emphasizing "acute" in acute decompensated heart failure
MDedge Internal Medicine
HFSA Roundtable, part 1: Beta-blockers remain heart failure management linchpin
MDedge Internal Medicine
VIDEO: HFSA Roundtable, part 2: Prevention offers best HFpEF strategy
MDedge Internal Medicine